2021
Clinical decision rule for obtaining peripheral blood cultures in febrile oncology patients
Gorfinkel L, Hansen CE, Teng W, Shabanova V, Prozora S, Rodwin R, Qadri U, Manghi T, Emerson B, Riera A. Clinical decision rule for obtaining peripheral blood cultures in febrile oncology patients. Pediatric Blood & Cancer 2021, 69: e29519. PMID: 34939321, DOI: 10.1002/pbc.29519.Peer-Reviewed Original ResearchConceptsPediatric emergency departmentPeripheral blood culturesPediatric oncology patientsFebrile oncology patientsClinical decision ruleOncology patientsBlood culturesBloodstream infectionsPositive peripheral blood cultureDiagnostic prediction toolsInternal validationRetrospective chart reviewAcute myeloid leukemia diagnosisRecent systematic reviewClinical prediction modelReceiver operator curveVasopressor supportActive therapyChart reviewDerivation cohortIndependent predictorsEmergency departmentPatientsSystematic reviewOperator curve
2014
Methylation of Twelve CpGs in Human Papillomavirus Type 16 (HPV16) as an Informative Biomarker for the Triage of Women Positive for HPV16 Infection
Brandsma JL, Harigopal M, Kiviat NB, Sun Y, Deng Y, Zelterman D, Lizardi PM, Shabanova VS, Levi A, Yaping T, Hu X, Feng Q. Methylation of Twelve CpGs in Human Papillomavirus Type 16 (HPV16) as an Informative Biomarker for the Triage of Women Positive for HPV16 Infection. Cancer Prevention Research 2014, 7: 526-533. PMID: 24556390, DOI: 10.1158/1940-6207.capr-13-0354.Peer-Reviewed Original ResearchConceptsCervical intraepithelial neoplasiaCytology samplesCutoff scoreColposcopy of womenCervical cancer preventionManagement of womenDetection of CIN3Cervical cytology samplesHuman papillomavirus type 16Human papillomavirus type 16 DNAMethylation biomarkersPapillomavirus type 16Histologic severityIntraepithelial neoplasiaCervical cancerHPV16 infectionCancer preventionDNA bisulfite sequencingType 16Prognostic potentialAccurate biomarkersProspective biomarkersScreening testInformative biomarkersBiomarkers
2011
“Change, before you have to.”–Jack Welch, Former CEO, General Electric*
Faustino EV, Lawson KA, Northrup V, Higgerson RA. “Change, before you have to.”–Jack Welch, Former CEO, General Electric*. Critical Care Medicine 2011, 40: 2227-2228. PMID: 21336130, PMCID: PMC3101274, DOI: 10.1097/ccm.0b013e31820eb8a1.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAge FactorsCase-Control StudiesCatheterization, Central VenousCause of DeathChildChild, PreschoolCritical CareCritical IllnessFemaleHospital MortalityHumansInfantIntensive Care Units, PediatricMalePrognosisReference ValuesRespiration, ArtificialRetrospective StudiesRisk AssessmentSex FactorsSurvival AnalysisTime FactorsTreatment OutcomeVenous ThrombosisConceptsVentilator-free daysIntensive care unitCentral venous lineDeep venous thrombosisDeep vein thrombosisIndex patientsVenous thrombosisCare unitMechanical ventilationIll childrenControl patientsVein thrombosisVenous lineIntensive care unit-free daysIntensive care unit stayPrevious prospective observational studyPediatric intensive care unitCentral venous line insertionSymptomatic venous thromboembolismVenous thrombosis studyProspective observational studyAlternative outcome measuresUnit stayVenous thromboembolismCohort study